Inspira Technologies is an innovative medical device company specializing in respiratory care solutions. The company’s flagship ART™ system utilizes a hemo-protective flow approach designed to rebalance oxygen saturation levels while patients are awake and breathing spontaneously, potentially minimizing the need for mechanical ventilation.
The ART TM System
Designed to directly oxygenate the blood at an early stage while the patient is awake and breathing spontaneously. The ART system acts as an “artificial lung” to rebalance patients’ oxygen saturation levels in one minute.
By inserting oxygen into the blood and removing CO2 from the blood, the ART system has the potential to minimize the need for mechanical ventilation.
The ART TM System Advantage
Designed to be affordable,
easy-to-use and require
less specialized personnel
to reduce operational costs
easy-to-use and require
less specialized personnel
to reduce operational costs
Potentially avoids long-term
effects of induced coma
effects of induced coma
Designed to reduce complications
associated with mechanical ventilation
associated with mechanical ventilation
Potentially eliminates risks of
lengthy weaning process
from mechanical ventilation
lengthy weaning process
from mechanical ventilation
Intended to expand acute
respiratory treatment
beyond the ICU
respiratory treatment
beyond the ICU
Aims to reduce length
of hospital stays and costs
of hospital stays and costs
News & Events
February 3, 2022
Inspira Technologies Appointed an Expert in the Field of Artificial Lung as the New Chief Technology Officer (CTO)
January 31, 2022
